2,336
Views
10
CrossRef citations to date
0
Altmetric
Article

Evaluation of the anti-inflammatory and antioxidant pharmcodynamic compoents of naoxintong capsules as a basis of broad spectrum effects

, , , , , , & show all
Pages 240-249 | Received 01 Feb 2020, Accepted 23 Dec 2020, Published online: 19 Apr 2021

References

  • Abeyrathna P, Su Y. 2015. The critical role of Akt in cardiovascular function. Vascul Pharmacol. 74:38–48.
  • Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. 2016. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 1:CD001800.
  • Busti C, Falcinelli E, Momi S, Gresele P. 2010. Matrix metalloproteinases and peripheral arterial disease. Intern Emerg Med. 5:13–25.
  • Chhibber-Goel J, Singhal V, Bhowmik D, Vivek R, Parakh N, Bhargava B, Sharma A. 2016. Linkages between oral commensal bacteria and atherosclerotic plaques in coronary artery disease patients. NPJ Biofilms Microbiomes. 2:7–19.
  • Dilly AK, Ekambaram P, Guo Y, Cai Y, Tucker SC, Fridman R, Kandouz M, Honn KV. 2013. Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-κB. Int J Cancer. 133:1784–1791.
  • Doss HM, Dey C, Sudandiradoss C, Rasool MK. 2016. Targeting inflammatory mediators with ferulic acid, a dietary polyphenol, for the suppression of monosodium urate crystal-induced inflammation in rats. Life Sci. 148:201–210.
  • Feng H, Wang Z, Wang C, Zhu X, Liu Z, Liu H, Guo M, Hou Q, Chu Z. 2019. Effect of furostanol saponins from Allium macrostemon Bunge bulbs on platelet aggregation rate and PI3K/Akt pathway in the rat model of coronary heart disease. Evid Based Complement Alternat Med. 2019:1–7.
  • Fu S, Gu Y, Jiang JQ, Chen X, Xu M, Chen X, Shen J. 2014. Calycosin-7-O-β-d-glucoside regulates nitric oxide /caveolin-1/matrix metalloproteinases pathway and protects blood-brain barrier integrity in experimental cerebral ischemia-reperfusion injury. J Ethnopharmacol. 155:692–701.
  • Gutiérrez E, Flammer AJ, Lerman LO, Elízaga J, Lerman A, Fernández-Avilés F. 2013. Endothelial dysfunction over the course of coronary artery disease. Eur Heart J. 34:3175–3181.
  • Han BH, Seo CS, Yoon JJ, Kim HY, Ahn YM, Eun SY, Hong MH, Lee JG, Shin HK, Lee HS, et al. 2018. The inhibitory effect of ojeoksan on early and advanced atherosclerosis. Nutrients. 10:1256–1279.
  • Hoesel B, Schmid JA. 2013. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 12:86–100.
  • Jiang X, Lv B, Li P, Ma X, Wang T, Zhou Q, Wang X, Gao X. 2015. Bioactivity-integrated UPLC/Q-TOF-MS of Danhong injection to identify NF-κB inhibitors and anti-inflammatory targets based on endothelial cell culture and network pharmacology. J Ethnopharmacol. 174:270–276.
  • Jiang YF, Liu ZQ, Cui W, Zhang WT, Gong JP, Wang XM, Zhang Y, Yang MJ. 2015. Antioxidant effect of salvianolic acid B on hippocampal CA1 neurons in mice with cerebral ischemia and reperfusion injury. Chin J Integr Med. 21:516–522.
  • Li SR, Wang TH, Zhang BJ. 2012. Effects of naoxintong capsule on the inflammation and prognosis in borderline lesion coronary heart disease patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 32:607–611.
  • Liang Q, Cai Y, Chen R, Chen W, Chen L, Xiao Y. 2018. The effect of naoxintong capsule in the treatment of patients with cerebral infarction and carotid atherosclerosis: a systematic review and meta-analysis of randomized trials. Evid Based Complement Alternat Med. 2018:1–9.
  • Lubos E, Handy DE, Loscalzo J. 2008. Role of oxidative stress and nitric oxide in atherothrombosis. Front Biosci. 13:5323–5344.
  • Lv P, Tong X, Peng Q, Liu Y, Jin H, Liu R, Sun W, Pan B, Zheng L, Huang Y. 2016. Treatment with the herbal medicine, naoxintong improves the protective effect of high-density lipoproteins on endothelial function in patients with type 2 diabetes. Mol Med Rep. 13:2007–2016.
  • Lv Y, Pan Y, Gao Y, Lu J, Li Y, Bai J, Zhai J. 2015. Effect of danhong injection combined with naoxintong tablets on prognosis and inflammatory factor expression in acute coronary syndrome patients undergoing percutaneous coronary intervention. Acta Cardiol Sin. 31:301–307.
  • Lyu Y, Jiang X, Dai W. 2015. The roles of a novel inflammatory neopterin in subjects with coronary atherosclerotic heart disease. Int Immunopharmacol. 24:169–172.
  • Ma L, Guan YQ, Du ZD. 2015. Salvianolic acid B down-regulates matrix metalloproteinase-9 activity and expression in tumor necrosis factor-α-induced human coronary artery endothelial cells. Chin Med J (Engl). 128:2658–2663.
  • Ma X, Huang F, Zhang Z, Song F, Ou S. 2016a. Lung cancer resection with concurrent off-pump coronary artery bypasses: safety and efficiency. J Thorac Dis. 8:2038–2045.
  • Ma X, Lv B, Li P, Jiang X, Zhou Q, Wang X, Gao X. 2016b. Identification of “multiple components-multiple targets-multiple pathways” associated with naoxintong capsule in the treatment of heart diseases using UPLC/Q-TOF-MS and network pharmacology. Evid Based Complement Alternat Med. 2016:9468087.
  • Mancuso C, Santangelo R. 2014. Ferulic acid: pharmacological and toxicological aspects. Food Chem Toxicol. 65:185–195.
  • Quan GH, Wang H, Cao J, Zhang Y, Wu D, Peng Q, Liu N, Sun WC. 2015. Calycosin suppresses RANKL-mediated osteoclastogenesis through inhibition of MAPKs and NF-κB. Int J Mol Sci. 16:29496–29507.
  • Shen D, Xie X, Zhu Z, Yu X, Liu H, Wang H, Fan H, Wang D, Jiang G, Hong M. 2014. Screening active components from Yu-ping-feng-san for regulating initiative key factors in allergic sensitization. PLoS One. 9:e107279.
  • Song HK, Kim J, Lee JS, Nho KJ, Jeong HC, Kim J, Ahn Y, Park WJ, Kim DH. 2015. Pik3ip1 modulates cardiac hypertrophy by inhibiting PI3K pathway. PLoS One. 10:e0122251.
  • Wang R, Dong LD, Meng XB, Shi Q, Sun WY. 2015. Unique microRNA signatures associated with early coronary atherosclerotic plaques. Biochem Biophys Res Commun. 464:574–579.
  • Wang Y, Yan X, Mi S, Li Z, Wang Y, Zhu H, Sun X, Zhao B, Zhao C, Zou Y, et al. 2017. Naoxintong attenuates ischaemia/reperfusion injury through inhibiting NLRP3 inflammasome activation. J Cell Mol Med. 21:4–12.
  • Wang Z, Shi H, Zhao H, Dong Z, Zhao B, Weng X, Liu R, Li X, Hu K, Zou Y, et al. 2018. Naoxintong retards atherosclerosis by inhibiting foam cell formation through activating Pparα Pathway. Curr Mol Med. 18:698–710.
  • Warzecha CC, Hovhannisyan R, Carstens RP. 2012. Dynamic fluorescent and luminescent reporters for cell-based splicing screens. Methods Mol Biol. 867:273–287.
  • Xu H, Jin J, Chen L, Li C, Xu Q, Shi J, Zhao B, Hou Y, Wang H. 2016. Naoxintong/PPARα signaling inhibits H9c2 cell apoptosis and autophagy in response to oxidative stress. Evid Based Complement Alternat Med. 2016:4370381.
  • Yang X, Li Y, Sun L, Liu Y, Ma C, Chen Y, Tan H, Li Q, Li X, Wang Y, et al. 2017. Naoxintong enhances atorvastatin-induced plaque stability while ameliorating atorvastatin-induced hepatic inflammation. J Cardiovasc Pharmacol. 69:55–64.
  • Yuan S, Jin J, Chen L, Hou Y, Wang H. 2017. Naoxintong/PPARγ signaling inhibits cardiac hypertrophy via activation of autophagy. Evid Based Complement Alternat Med. 2017:3801976.
  • Zhai C, Cheng J, Mujahid H, Wang H, Kong J, Yin Y, Li J, Zhang Y, Ji X, Chen W. 2014. Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque. PLoS One. 9:e90563.
  • Zhang F, Huang B, Zhao Y, Tang S, Xu H, Wang L, Liang R, Yang H. 2013. BNC protects H9c2 cardiomyoblasts from H2O2 -induced oxidative injury through ERK1/2 signaling pathway. Evid Based Complement Alternat Med. 2013:802784.
  • Zhang X, Qi LW, Yi L, Li P, Wen XD, Yu QT. 2008. Screening and identification of potential bioactive components in a combined prescription of Danggui Buxue decoction using cell extraction coupled with high performance liquid chromatography. Biomed Chromatogr. 22:157–163.
  • Zhang Z, Li K. 2018. Curcumin attenuates high glucose-induced inflammatory injury through the reactive oxygen species-phosphoinositide 3-kinase/protein kinase B-nuclear factor-κB signaling pathway in rat thoracic aorta endothelial cells. J Diabetes Investig. 9:731–740.
  • Zhao S, Tang Y, Cai H, Liu W, Zhang L, Chen D, Chen B. 2018. Treatment of Danhong injection combined with Naoxintong capsule in acute coronary syndrome patients undergoing PCI operation: study for a randomized controlled and double-blind trial. Evid Based Complement Alternat Med. 2018:8485472.
  • Zhong XN, Wang HH, Lu ZQ, Dai YQ, Huang JH, Qiu W, Shu YQ, Xu W, Cheng C, Hu XQ. 2013. Effects of Naoxintong on atherosclerosis and inducible nitric oxide synthase expression in atherosclerotic rabbit. Chin Med J (Engl). 126:1166–1170.
  • Zhou M, Ma X, Sun J, Ding G, Cui Q, Miao Y, Hou Y, Jiang M, Bai G. 2017. Active fragments-guided drug discovery and design of selective tropane alkaloids using ultra-high performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry coupled with virtual calculation and biological evaluation. Anal Bioanal Chem. 409:1145–1157.
  • Zhou Z, Liu Y, Miao AD, Wang SQ. 2005. Salvianolic acid B attenuates plasminogen activator inhibitor type 1 production in TNF-alpha treated human umbilical vein endothelial cells. J Cell Biochem. 96:109–116.